Table 4 Distribution of baseline demographic, disease-related clinical, laboratory and radiological data in RA-ILD patients with and without progression

Gender (female)

26/43 (60.5%)

19/34 (55.9%)

0.816

Probable UIP patern

23/43 (53.5%)

24/34 (70.6%)

0.161

Definite UIP patern with honey combing

6/43 (14%)

9/34 (26.5%)

0.247

NSIP

7/43 (16.3%)

6/34 (17.6%)

1.000

Cough

10/35 (23.3%)

32/32 (37.5%)

0.603

Dyspnea

10/35 (23.3%)

7/32 (20.6%)

0.584

Velcro crackles

12/34 (27.9%)

12/32 (35.3%)

1.000

Smoking

11/38 (25.6%)

11/26 (32.4%)

0.542

Anti-CCP (positive)

35/42 (81.4%)

28/34 (82.4%)

0.793

Anti-RF (positive)

32/42 (74.4%)

24/33 (70.6%)

1.000

Worsening respiratory symptoms

10/33 (23.3%)

10/28 (29.4%)

0.786

Age at RA diagnosis

55.34 ± 11.61

52.90 ± 9.7

0.529

Disease duration at ILD diagnosis

6.34 ± 6.4

6.93 ± 6.87

0.687

Age at ILD diagnosis

61.3 ± 9.27

59.7 ± 7.91

0.593

Baseline Warrick Severity score

4.95 ± 2.72

5.65 ± 3.02

0.331

Baseline Warrick Extent score

4.84 ± 2.62

5.38 ± 2.92

0.548

Baseline Warrick Total score

9.79 ± 5.13

11.03 ± 5.70

0.428

Baseline DAS28-ESR

3.57 ± 1.34

3.04 ± 1.08

0.117

Smoking (pack/year)

21.80 ± 16.10

23.36 ± 14.51

0.949

FVC % at ILD diagnosis

88.81 ± 14.98

83.44 ± 18.82

0.598

DLCO % at ILD diagnosis

64.38 ± 23.94

63.88 ± 19.51

0.949

Anti-RF titer

348 ± 681

361 ± 748

0.786

Anti-CCP titer

154 ± 207

290 ± 389

0.141